| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Praluzatamab ravtansine | CX-2009 | Phase 2 Clinical | Immunogen Inc, Cytomx Therapeutics Inc | Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |

